In November 2024, the U.S. FDA granted accelerated approval to zanidatamab, the world’s first HER2 dual-epitope dual antibody, for treating previously treated, unresectable, or metastatic HER2 overexpression (IHC 3+) biliary tract cancer in adults. This evidence concerns the gene ERBB2 and biliary tract cancer.